Teva Drug Patent Portfolio

Teva owns 3 orange book drugs protected by 35 US patents Given below is the list of Teva's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11311488 Osmotic dosage forms comprising deutetrabenazine and methods of use thereof 10 Jun, 2041
Active
US11179386 Analogs of deutetrabenazine, their preparation and use 15 Sep, 2038
Active
US11813232 Analogs of deutetrabenazine, their preparation and use 15 Sep, 2038
Active
US11179386 Analogs of deutetrabenazine, their preparation and use 15 Mar, 2038
Active
US11813232 Analogs of deutetrabenazine, their preparation and use 15 Mar, 2038
Active
US10959996 Methods for the treatment of abnormal involuntary movement disorders 07 Sep, 2036
Active
US11357772 Methods for the treatment of abnormal involuntary movement disorders 07 Sep, 2036
Active
US11446291 Methods for the treatment of abnormal involuntary movement disorders 07 Sep, 2036
Active
US11564917 Methods for the treatment of abnormal involuntary movement disorders 07 Sep, 2036
Active
US11648244 Methods for the treatment of abnormal involuntary movement disorders 07 Sep, 2036
Active
US12016858 Methods for the treatment of abnormal involuntary movement disorders 07 Sep, 2036
Active
US10959996 Methods for the treatment of abnormal involuntary movement disorders 07 Mar, 2036
Active
US11357772 Methods for the treatment of abnormal involuntary movement disorders 07 Mar, 2036
Active
US11446291 Methods for the treatment of abnormal involuntary movement disorders 07 Mar, 2036
Active
US11564917 Methods for the treatment of abnormal involuntary movement disorders 07 Mar, 2036
Active
US11648244 Methods for the treatment of abnormal involuntary movement disorders 07 Mar, 2036
Active
US12016858 Methods for the treatment of abnormal involuntary movement disorders 07 Mar, 2036
Active
US9550780 Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 18 Mar, 2034
Active
US9550780 Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 18 Sep, 2033
Active
US9023897 Biodegradable drug delivery compositions 05 Apr, 2033
Active
US8524733 Benzoquinoline inhibitors of vesicular monoamine transporter 2 03 Oct, 2031
Active
US8524733 Benzoquinoline inhibitors of vesicular monoamine transporter 2 03 Apr, 2031
Active
US8221778 Drug-containing implants and methods of use thereof 12 Nov, 2027
Active
US8741327 Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant 12 Nov, 2027
Active
US7815942 Rasagiline formulations of improved content uniformity 27 Aug, 2027
Active
US7572834 Rasagiline formulations and processes for their preparation 05 Dec, 2026
Active
US10736965 Risperidone biodegradable implant 12 Jan, 2025
Active
US8802127 Risperidone-containing PLA:PGA implants and methods of use thereof 12 Jan, 2025
Active
US9439905 Risperidone-containing implants and methods of use thereof 12 Jan, 2025
Active
US9717799 Drug-containing implants and methods of use thereof 12 Jan, 2025
Active
US9895447 Drug-containing PLA implants and methods of use thereof 12 Jan, 2025
Active
US9925268 Drug-containing implants and methods of use thereof 12 Jan, 2025
Active
US5453446 Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease. 07 Feb, 2017 Expired
US6126968 Stable compositions containing N-propargyl-1-aminoindan 18 Sep, 2016 Expired
US5532415 R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof 02 Jul, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Teva.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 20 Jun, 2024 US9550780
Surcharge for Late Payment, Large Entity 17 Apr, 2024 US10736965
Payment of Maintenance Fee, 4th Year, Large Entity 17 Apr, 2024 US10736965
Maintenance Fee Reminder Mailed 01 Apr, 2024 US10736965
Payment of Maintenance Fee, 8th Year, Large Entity 28 Feb, 2024 US9439905
Payment of Maintenance Fee, 12th Yr, Small Entity 03 Jan, 2024 US8221778
Mail Patent eGrant Notification 14 Nov, 2023 US11813232
Recordation of Patent eGrant 14 Nov, 2023 US11813232
Patent eGrant Notification 14 Nov, 2023 US11813232
Patent Issue Date Used in PTA Calculation 14 Nov, 2023 US11813232
Email Notification 14 Nov, 2023 US11813232
Recordation of Patent Grant Mailed 14 Nov, 2023 US11813232
Email Notification 27 Oct, 2023 US11813232
Issue Notification Mailed 25 Oct, 2023 US11813232
Application Is Considered Ready for Issue 16 Oct, 2023 US11813232


Teva's Drug Patent Litigations

Teva's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 08, 2021, against patent number US8524733. The petitioner Apotex Inc., challenged the validity of this patent, with Auspex Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Teva's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8524733 September, 2021 Terminated-Denied
(09 Mar, 2022)
Auspex Pharmaceuticals, Inc. Apotex Inc.


Teva Drug Patents' Oppositions Filed in EPO

Teva drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 13, 2017, by Generics (U.K.) Limited. This opposition was filed on patent number EP06720975A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP06720975A Feb, 2017 Generics (U.K.) Limited Patent maintained as amended


Teva's Family Patents

Teva drugs have patent protection in a total of 35 countries. It's US patent count contributes only to 33.5% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Teva Drug List

Given below is the complete list of Teva's drugs and the patents protecting them.


1. Austedo Xr

Austedo Xr is protected by 21 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11311488 Osmotic dosage forms comprising deutetrabenazine and methods of use thereof 10 Jun, 2041
(16 years from now)
Active
US11179386
(Pediatric)
Analogs of deutetrabenazine, their preparation and use 15 Sep, 2038
(13 years from now)
Active
US11813232
(Pediatric)
Analogs of deutetrabenazine, their preparation and use 15 Sep, 2038
(13 years from now)
Active
US11179386 Analogs of deutetrabenazine, their preparation and use 15 Mar, 2038
(13 years from now)
Active
US11813232 Analogs of deutetrabenazine, their preparation and use 15 Mar, 2038
(13 years from now)
Active
US10959996
(Pediatric)
Methods for the treatment of abnormal involuntary movement disorders 07 Sep, 2036
(11 years from now)
Active
US11357772
(Pediatric)
Methods for the treatment of abnormal involuntary movement disorders 07 Sep, 2036
(11 years from now)
Active
US11446291
(Pediatric)
Methods for the treatment of abnormal involuntary movement disorders 07 Sep, 2036
(11 years from now)
Active
US11564917
(Pediatric)
Methods for the treatment of abnormal involuntary movement disorders 07 Sep, 2036
(11 years from now)
Active
US11648244
(Pediatric)
Methods for the treatment of abnormal involuntary movement disorders 07 Sep, 2036
(11 years from now)
Active
US12016858
(Pediatric)
Methods for the treatment of abnormal involuntary movement disorders 07 Sep, 2036
(11 years from now)
Active
US10959996 Methods for the treatment of abnormal involuntary movement disorders 07 Mar, 2036
(11 years from now)
Active
US11357772 Methods for the treatment of abnormal involuntary movement disorders 07 Mar, 2036
(11 years from now)
Active
US11446291 Methods for the treatment of abnormal involuntary movement disorders 07 Mar, 2036
(11 years from now)
Active
US11564917 Methods for the treatment of abnormal involuntary movement disorders 07 Mar, 2036
(11 years from now)
Active
US11648244 Methods for the treatment of abnormal involuntary movement disorders 07 Mar, 2036
(11 years from now)
Active
US12016858 Methods for the treatment of abnormal involuntary movement disorders 07 Mar, 2036
(11 years from now)
Active
US9550780
(Pediatric)
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 18 Mar, 2034
(9 years from now)
Active
US9550780 Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 18 Sep, 2033
(8 years from now)
Active
US8524733
(Pediatric)
Benzoquinoline inhibitors of vesicular monoamine transporter 2 03 Oct, 2031
(6 years from now)
Active
US8524733 Benzoquinoline inhibitors of vesicular monoamine transporter 2 03 Apr, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Austedo Xr's drug page


2. Azilect

Azilect is protected by 5 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7815942 Rasagiline formulations of improved content uniformity 27 Aug, 2027
(2 years from now)
Active
US7572834 Rasagiline formulations and processes for their preparation 05 Dec, 2026
(2 years from now)
Active
US5453446 Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease. 07 Feb, 2017
(7 years ago)
Expired
US6126968 Stable compositions containing N-propargyl-1-aminoindan 18 Sep, 2016
(8 years ago)
Expired
US5532415 R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof 02 Jul, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Azilect's drug page


3. Uzedy

Uzedy is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9023897 Biodegradable drug delivery compositions 05 Apr, 2033
(8 years from now)
Active
US8221778 Drug-containing implants and methods of use thereof 12 Nov, 2027
(3 years from now)
Active
US8741327 Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant 12 Nov, 2027
(3 years from now)
Active
US10736965 Risperidone biodegradable implant 12 Jan, 2025
(2 months from now)
Active
US8802127 Risperidone-containing PLA:PGA implants and methods of use thereof 12 Jan, 2025
(2 months from now)
Active
US9439905 Risperidone-containing implants and methods of use thereof 12 Jan, 2025
(2 months from now)
Active
US9717799 Drug-containing implants and methods of use thereof 12 Jan, 2025
(2 months from now)
Active
US9895447 Drug-containing PLA implants and methods of use thereof 12 Jan, 2025
(2 months from now)
Active
US9925268 Drug-containing implants and methods of use thereof 12 Jan, 2025
(2 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Uzedy's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Teva News

FDA grants approval to Fresenius Kabi for biosimilar of Stelara called Otulfi, announces Pharmaceutical Technology

01 Oct, 2024

Cigna removes Humira by AbbVie from its formularies, increasing the strain on the blockbuster drug.

27 Aug, 2024

Ozempic from Novo Nordisk is a potential candidate for price negotiation with Medicare in 2027

23 Aug, 2024

Explanation of the misuse of the US pharmaceutical patent system - Chemistry World

11 Jul, 2024

See More